Alpha-1 antitrypsin deficiency (AATD) is highly prevalent in Portugal. It is estimated that 1:
5249 individuals have a ZZ genotype, and 1: 281 have a SZ genotype [1]. Patients with …

The clinical manifestations of COVID-19 are heterogeneous: 46.4% of patients admitted into
hospital reported to have at least one comorbidity. Comorbidities such as COPD, diabetes …

Introduction Alpha-1-antitrypsin (AAT) has been shown to inhibit SARS-CoV-2 cell entry and
suggested as a therapeutic agent for COVID-19. Furthermore, epidemiological association …

Patients with severe alpha-1 antitrypsin deficiency (AATD) have increased risk of developing
chronic, progressive lung disease, particularly pan-lobular emphysema. 1 P athogenesis is …

At the time when WHO reports that Italy is currently the fifth country in the world for number of
cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection (225 …

Background: Epidemiologic studies have reported that the geographical distribution of the
prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of …

Methods The association between A1AT deficiency and SARS-COV-2 was explored using
data from the Spanish COalition to Unlock Research on host GEnetics (SCOURGE) study on …

Abstract Introduction Alpha 1 antitrypsin (A1AT) is the major human blood serine protease
inhibitor. Transmembrane serine protease 2 (TMPRSS2), which is crucial for SARS-CoV-2 …

Alpha1-antitrypsin deficiency arises due to mutations in alpha1-antitrypsin (AAT) gene and
represents the most prominent genetic predisposition to chronic obstructive pulmonary …

Respiratory function deficits are common sequelae for COVID-19. In this study, we aimed to
identify the medical conditions that may influence lung function impairment at 12 months …